SPARK translational medicine program
The only topical epithelial regenerator for the oral cavity that has shown, in vivo, to prevent the incidence and severity of radiation induced oral mucositis. Tumor xenograft models have alleviated tumor promotion concerns with an excellent safety and toxicity profile.
The only topical epithelial regenerator for the oral cavity that has shown, in vivo, to prevent the incidence and severity of radiation induced oral mucositis. Tumor xenograft models have alleviated tumor promotion concerns with an excellent safety and toxicity profile.
Company Type:
Privately Funded Company
Company Website:
Company HQ State:
California
Company HQ Country:
United States
Year Founded:
2020
Main Therapeutic Focus:
Infectious Diseases
Lead Product in Development:
HB-EGF for oral mucositis
Development Phase of Primary Product:
Pre-Clinical
Number Of Unlicensed Products (For Which You Are Seeking Partners):
2
Speaker
